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Understanding the evolution of the direct and indirect
pathways of allorecognition following tissue trans-
plantation is essential in the design of tolerance-
promoting protocols. On the basis that donor bone
marrow–derived antigen-presenting cells are elimi-
nated within days of transplantation, it has been
argued that the indirect response represents the
major threat to long-term transplant survival, and is
consequently the key target for regulation. However,
the detection of MHC transfer between cells, and par-
ticularly the capture of MHC:peptide complexes by
dendritic cells (DCs), led us to propose a third, semidi-
rect, pathway of MHC allorecognition. Persistence of
this pathway would lead to sustained activation of
direct-pathway T cells, arguably persisting for the life
of the transplant. In this study, we focused on the
contribution of acquired MHC-class I on recipient DCs
during the life span of a skin graft. We observed that
MHC-class I acquisition by recipient DCs occurs for at
least 1 month following transplantation and may be
the main source of alloantigen that drives CD8+ cyto-
toxic T cell responses. In addition, acquired MHC-class
I:peptide complexes stimulate T cell responses
in vivo, further emphasizing the need to regulate both
pathways to induce indefinite survival of the graft.
Abbreviations: cDC, conventional dendritic cell; DC,
dendritic cell; DT, diphtheria toxin; sdLN, skin-
draining lymph node
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Introduction
The major obstacle to transplantation success is the recog-
nition by the recipient immune system of donor major his-
tocompatibility complex (MHC molecules) (1,2). Two
major pathways have been identified. The first is the “di-
rect pathway” in which donor dendritic cells (DCs) present
intact donor MHC–peptide complexes to recipient T cells.
This pathway is characterized by a very high frequency of
T cells specific for alloantigens (3,4). The second, “indirect
pathway” of allorecognition involves the presentation of
peptides derived from donor MHC molecules by recipient
DCs. Based on the fact that donor-derived DCs are elimi-
nated within days of transplantation, it has been argued
that the indirect response represents the major threat to
long-term transplant survival, and is consequently the key
target for regulation. However, since we proposed the
existence of the third pathway of allorecognition, based on
the evidence that intact MHC-class I molecules can be
transferred between DC subsets and between DCs and
endothelial as well as epithelial cells, this assumption has
been challenged (5–8). The discovery of this new pathway
of allorecognition suggests that the direct pathway could
last for the life of the transplant and pose another chal-
lenge for the induction of long-term transplant survival (6).
So far, the contribution of acquired MHC-class I mole-
cules has been assessed only at early time points. In
both heart and kidney transplant settings, transfer of
intact allo-MHC to recipient DCs has been demonstrated
at days 1–5 posttransplant for heart (9) and day 8 for
kidney (10) in the heart transplant model the transferred
MHC led to priming of both humoral and cellular
alloimmunity (9).
In addition, the capacity of the transfer of donor-MHC
molecules to activate T cells with direct allospecificity
has not been tested. Recently, Celli et al (2011) elegantly
demonstrated, using intravital imaging, that following
skin transplantation, donor-derived dermal DCs migrated
out of the transplant and that this occurs before recipient
1
© Copyright 2016 The Authors. American Journal of Transplantation published by
Wiley Periodicals, Inc. on behalf of American Society of
Transplant Surgeons
doi: 10.1111/ajt.13996
American Journal of Transplantation 2016; XX: 1–9
Wiley Periodicals Inc.
CD11b+ mononuclear cells, which consisted of neu-
trophils, mononuclear cells, and inflammatory DCs,
arrived at the transplant site (11). Recipient CD11b+
cells acquired and presented alloantigen (via cross-
presentation) to CD8+ T cells in the skin-draining lymph
node (sdLN) (11). Given that donor dermal DCs leave the
transplant and that host infiltrating CD11b+ cells return to
the sdLN carrying antigen present in the transplant, in
the above model, it is possible that alloantigen in the
form of intact allo-MHC class I is acquired in two differ-
ent ways. Firstly, recipient resident DCs, present in the
spleen and dLN, could acquire MHC-class I from donor
dermal DCs, or secondly recipient graft-infiltrating cells
by sampling the parenchymal cells could acquire MHC
molecules and then traffic to the sdLN. Given that MHC-
class I is present throughout the life span of the graft, it
is feasible that acquisition of allo-MHC molecules by
recipient DCs drives CD8+ T cell responses even at late
time points after transplantation.
To test these hypotheses, MHC-class I transfer was
evaluated in indirect (also referred to as cross-
presentation or cross-priming) pathway deficient
recipient mice (12), in the absence and presence of
donor-derived DCs.
Materials and Methods
Mice
C57BL/6 (H-2b) mice, 6–10 weeks of age were purchased from Harlan
Olac (Bicester, UK). B6.CD11c-GFP-DTR mice (CD11c.DTR.GFP mice),
Transgenic B6 mice expressing membrane-bound chicken ovalbumin
(Actin-mOVA mice, a kind gift from Dr Randy Noelle), OT-1Rag/ and
H-2KBm1 mice were bred and maintained under sterile conditions. B6.Kd
were a kind gift from Pat Bucy. B6.Batf3/ (Batf3/) mice were a kind
gift from Dr Kenneth Murphy (Washington University School of Medicine)
(12). Mouse handling and experimental procedures were conducted in
accordance with the Home Office Animals Scientific Procedures Act of
1986.
Cell culture medium
Cell cultures were performed in RPMI 1640 (Sigma, Poole, UK) medium
supplemented with 100 IU/mL penicillin, 100 lg/mL streptomycin, 2 mM
L-glutamine, 0.01M N-2-hydroxyethylpiperazine-N0-2-ethanesulfonic acid,
50 lM 2b-mercaptoethanol (Thermo Fisher, Paisley, UK), and 10% heat-
inactivated fetal calf serum (FCS) (SERAQ, Sussex, UK). Cells were main-
tained at 37°C in a humidified atmosphere with 5% CO2.
Antibodies and flow cytometry
All the mAbs used, unless stated otherwise, were purchased from Affy-
metrix eBiosciences, Cheshire, UK. Fluorochrome-conjugated (fluorescein
isothiocyanate, phycoerythrin [PE], allophycocyanin [APC]) mAbs against
the following mouse cell-surface antigens—CD11c, Va2, and CD8—were
used with their relevant isotype controls. For flow cytometry analysis,
cells were labeled with fluorochrome-conjugated mAbs for 30 min at 4°C,
washed twice in FACS buffer (phosphate-buffered saline/2% FCS/0.1%
sodium azide), and analyzed on a FACSCaliburTM, using the Cell QuestTM
software (Becton Dickinson, Mountain View, CA). Subsequent off-line
analysis was performed with FlowJo software (Treestar, Ashland, OR).
Purification and labeling of CD8+ T cells
Responder T cells were purified from red blood cell (RBC)–depleted
splenocytes isolated from OT-1 Rag/ mice. A single-cell suspension
was obtained by passing spleens and/or pooled lymph nodes through a
70-lm cell strainer (Fisher Scientific, Loughborough, UK). Erythrocytes
were lysed using ACK buffer (0.15M NH4Cl/1 mM KHCO3/0.1 mM Na2-
EDTA). The purity of responder T cells was consistently between 90%
and 95%. T cells were labeled with 1 lM of Vybrant CFDA SE (CFSE (5)
and -6)- Carboxyflourescein Diacetate, Succinimidyl Ester) (Thermo Fisher)
according to the manufacturer’s instructions before being injected.
Skin grafting
Skin grafting was done according to the technique described by Billing-
ham and Medawar (13) with some modifications. Full-thickness donor tail
skin (0.5–1 9 0.5–1 cm) was grafted on beds prepared on the right lateral
flank of recipients. The graft site was protected by a waterproof plaster
(Elastoplast, Birmingham, UK), which was removed on day 7. The grafts
were observed every day afterwards and considered rejected when no
viable skin remained. Graft survival between two groups was compared
using the log-rank test.
MHC-class I transfer experiments
Following transplantation, some recipient Batf3/ mice were injected i.v.
with 200 lg of dsRNA (polyinosinic-polycytidylic acid) to ensure a block in
cross-presentation in the presence or absence of 4 ng/g body weight of
diphtheria toxin (DT) (Sigma-Aldrich, Dorset, UK) via i.v. and i.p. injection to
remove the GFPhi DCs as described by Prlic et al (14). H-2KBm1 mice that
received a transplant were injected with DT only. One day later, 4 9 106
CFSE-labeled T cells isolated from OT-1Rag/ mice were adoptively trans-
ferred i.v. T cell proliferation was measured on day 3 following adoptive
transfer of the labeled T cells via flow cytometry following staining with an
anti-Va2-PE antibody specific to the transgenic T cells and an anti-CD8a-
APC.
Additionally, CD11c.DTR.GFP mice received a B6.Kd skin transplant, and
7 days later mice were treated with picryl chloride (2-chloro-1,3,5-trinitro-
benzene, Sigma Aldrich) for 4 days. Spleens were harvested and RBC-
depleted splenocytes were stained with antibodies to CD11c and Kd.
Expression of Kd on cells was measured by flow cytometry.
T cell proliferation and cytokine assays
For in vitro studies, T cells from OT-1 Rag/ mice were isolated using a
CD8+ T cell isolation kit (Miltenyi Biotech, Surrey, UK). The purity of
responder T cells was assessed using PE-conjugated anti-CD8 antibodies
(clone 53-6.7). The purity of T cells was consistently between 90% and
95%. CD11c selected DCs were isolated using a CD11c isolation kit (Mil-
tenyi Biotech) following manufacturers’ instructions. 105 purified CD8+ T
cells and 105 CD11c were stimulated in triplicate wells of a 96-well plate.
T cell proliferation was measured by [3H] thymidine incorporation after
3 days in culture. Results are shown as mean count per minute of tripli-
cate determinations  SD. To measure interferon-c (IFNc) production,
culture supernatant, taken from the above cultures, were analyzed using
an IFNc-specific enzyme-linked immunosorbent assay (ELISA) kit, follow-
ing manufacturer’s instructions (eBioscience). Results are shown as
mean pg/mL of triplicate determinations  SD.
Statistical analysis
Data are represented as mean  standard error of the mean where
appropriate. Graft survival was depicted using Kaplan–Meier analysis and
groups were compared by log-rank (Mantel–Cox) testing. To determine
statistical significance, a Student’s t-test (unpaired, two-tailed) was car-
ried out using the GraphPad Prism software, http://www.graphpad.com/
prism/prism.htm. In the figures, p-values <0.05 are indicated by *,
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p < 0.01 by **, and p < 0.001 by ***, whereas nonsignificant p-values
are labeled “ns.” Values of p < 0.05 were considered significant.
Results
mOVA-expressing skin allografts are rejected in the
absence of CD8a+ and CD103+ DCs
Rejection of skin expressing OVA, a single minor mis-
match antigen, has previously been shown in B6 recipi-
ent mice (15). Injection of OVA-specific CD8+ T cells,
isolated from OT-1 T cell receptor (TCR)–transgenic mice,
into these transplanted B6 mice indicated the presence
of OVA antigen in both sdLNs and spleen following skin
transplantation (15). Activation of these T cells may be
due to recognition of antigen in a variety of ways includ-
ing antigen presented by donor DCs, direct recognition,
or cross-presentation by recipient DCs, or by recipient
DCs presenting acquired MHC-peptide complexes from
the transplanted tissues. To assess the contribution of
cross-presentation in this model, we compared the rejec-
tion kinetics of Act-mOVA skin in B6 mice and Batf3/
recipient mice (H-2b). Batf3/ mice lack CD8a+ conven-
tional DCs (cDCs), the DC subset regarded as the main
cross-presenters, as well as the nonlymphoid CD103+
migratory cDC population. In comparison to B6 mice, Bat-
f3/ mice reject OVA skin transplants at a slower rate
(mean survival time was 25 days on B6 recipients com-
pared to 32 days on Batf3/ recipients, Figure 1A) sug-
gesting that either, or both, the CD8a+ and the CD103
DC subset contribute to the rejection of skin transplants
in the B6 mice. However, Act-mOVA, but not control B6
skin transplants, were rejected by Batf3/ mice even in
the absence of these cross-presenting DC subsets
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Figure 1: Act-mOVA skin grafts are rejected in the absence of cross-presentation. (A) Batf3/ mice received either an Act-
mOVA or a B6 skin transplant whereas B6 mice received only Act-mOVA skin. Mice were monitored daily, and rejection was deemed
as the day when no viable skin remained. ***p < 0.001 (Kaplan–Meier). Data are representative of three experiments with five mice
per condition. (B) Batf3/ mice were injected with 4 9 106 CFSE-labeled OT-1Rag/ T cells on days 10, 14, 21, or 30 post Act-
mOVA skin transplantation. Control mice received CFSE-labeled T cells only (no transplant). After 3 days, proliferation of OVA-specific
T cells in the spleen (SPLN) and draining lymph nodes (dLNs) was measured. Cells were stained with antibodies to Va2 and CD8 and
CFSE dilution measured on Va2+CD8a+ only cells by flow cytometry. Panels represent the histogram profile of CFSE staining of T
cells isolated for an individual mouse. Gray-filled histograms represent the proliferation profile of OT-1Rag/ T cells in control mice,
whereas the black histograms represent the proliferation profile of OT-1Rag/ T cells in Act-mOVA skin transplant recipients. Data
shown are representative of three experiments.
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(Figure 1A). Next we measured OVA-specific CD8+ T cell
response in the Batf3/ recipient mice receiving Act-
mOVA skin. Injection of CFSE-labeled CD8+ T cells, iso-
lated from OT-1Rag/ mice, into transplanted mice on
days 10, 14, 21, and 30 after transplantation resulted in T
cell proliferation, measured 72 h later by CFSE dilution,
at all time points (Figure 1B). The data therefore indicate
that OVA antigen was present in the spleen and sdLN for
a prolonged period (Figure 1B). Interestingly, even when
there was very little skin left, day 30, posttransplant, T
cell proliferation was still observed.
MHC-class I molecules are acquired throughout the
life span of the transplanted skin
The aforementioned observations suggest that the pre-
sentation of OVA by either donor DCs or via the acquisi-
tion of intact MHC:peptide complexes by recipient DCs
drives T cell proliferation following transplantation in the
Batf3/ mice. To assess the contribution of MHC-class
I:OVA peptide complexes, acquired by recipient DCs, and
to exclude the contribution of donor-derived DCs directly
presenting OVA peptide, to CD8+ T cells, Act-mOVA-
expressing mice were crossed with CD11c.DTR.GFP
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Figure 2: Donor DCs present after transplantation can be removed following treatment with DT. (A) Batf3/ mice received an
Act-mOVAxDTR/GFP skin transplant and 14 days later some mice received 4 ng/g body weight of DT. Control mice received no DT.
After 24 h the presence of CD11c+ cells expressing GFP was assessed by flow cytometry. (B) Batf3/ mice received Act-
mOVAxDTR/GFP a skin transplant and the presence of CD11c+ cells expressing GFP was assessed by flow cytometry 10, 14, and
30 days posttransplant. Panels represent the dot-plot profile of CD11c versus GFP expression on live cells for each individual mouse.
(C) Spleens isolated from B6 (left) and Batf3/ (right) mice 14 days posttransplant were stained with antibodies to CD8 and CD11c.
Panels represent the contour prolife of CD11c versus CD8 expression on live cells for each individual mouse. The data shown are rep-
resentative of three experiments. DCs, dendritic cells; DT, diphtheria toxin; SPLN, spleen.
Figure 3: Donor MHC-class I molecules are acquired throughout the life span of the transplant and can induce CD8+ T cell
responses. Batf3/ mice received an Act-mOVAxDTR/GFP skin transplant and 14 (A) or 30 days (B) posttransplant; some mice
received 4 ng/g of DT and 200 lg of dsRNA (left panels) 24 h prior to injection of CFSE-labeled OT-1Rag/ T cells. Control, trans-
planted mice received no DT (middle panels). After 3 days, proliferation of OT-1Rag/ T cells, identified using antibodies to Va2 and
CD8, in the spleen (SPLN) and draining lymph node cells (dLNs) was measured by flow cytometry. Control mice received CFSE-
labeled OT-1Rag/ T cells only (right panels). Histograms shown represent the proliferation of CD8a, Va2, and CFSE-positive cells for
an individual mouse. The percentage proliferation of OT-1Rag/ T cells, from five mice per group, is shown. Each dot represents an
individual mouse. Statistical analysis using an unpaired t-test with no significant difference denoted as NS. DT, diphtheria toxin.
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mice. In doing so, we created a model in which donor
DCs, presenting MHC-class I molecules and OVA pep-
tide, could be removed by using DT, following Act-
mOVAxDTR/GFP skin transplantation (Figure 2A).
Although it has been reported that donor-derived DCs
are killed quickly following transplantation in a fully mis-
matched setting (16), donor-derived DCs, as measured
using CD11c+GFP+ expression, were observed in the
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spleen of recipient mice up to 14 days after transplanta-
tion. However, after 30 days donor DCs were completely
absent (Figure 2B). No donor-derived DCs were observed
in the dLNs at any time point assessed (data not shown),
suggesting that too few of these cells were present in
this location in our experimental setup.
To remove donor DCs, recipient Batf3/ mice were trea-
ted with DT, as previously published (8), 14 and 30 days
post skin transplantation. It has been reported that under
inflammatory conditions, CD8a+ DCs develop in the
Baft3/ mice, although very few CD8a+ DCs were present
in the spleens day 14 posttransplant (Figure 2C). However,
to completely circumvent this possibility, we injected recipi-
ent mice with dsRNA intravenously as we, and others,
have previously shown that this treatment results in the
depletion of CD8a+ DCs (8). Importantly, when OVA-speci-
fic OT-1Rag/ T cells were injected 24 h, or 72 h (data not
shown), after depletion of donor DCs using DT and dsRNA
treatment, proliferation was observed in both the spleen
and the sdLN of the recipient mice (Figures 3A and B).
Importantly, no significant differences in the overall T cell
responses were observed in the presence or absence of
donor DCs. These findings suggest that at days 14 and 30
posttransplantation it was the recipient DCs that were pre-
senting antigen to the T cells in this model. As expected,
less T cell proliferation was observed over time due to a
diminishing antigen load as the graft was rejected.
Taken together, the data suggest that the acquisition of
MHC-class I:peptide complexes from either donor
parenchymal cells or dying donor DCs by recipient APCs
drives antigen-specific CD8+ T cell responses throughout
the life span of the transplant.
Recipient-derived DCs acquire MHC-class I molecules
from donor cells
To confirm that donor MHC-class I molecules, present
on graft tissue, were acquired by recipient DCs and
presented to T cells in the dLNs, we repeated the Act-
mOVAxDTR/GFP skin transplants using H-2KBm1 recipi-
ent mice. We have previously shown that DCs isolated
from H-2KBm1 do not cross-present either soluble or cell-
associated OVA to OT-1 T cells (1,8). However, these
DCs can present acquired MHC:OVA complexes to
OT-1Rag/ T cells (1,8). Transplanted mice were treated
with DT 14 days after transplantation, control mice
received no DT, and 1 day later mice received CFSE-
labeled OT-1 T cells. As expected from our previous
observations in the Baft3/ recipients, no significant dif-
ferences in the overall T cell responses were observed
in the presence or absence of donor DCs (Figure 4A).
These findings confirm that in the absence of cross-pre-
sentation, recipient DCs acquire donor MHC:peptide and
activate CD8+ T cells in vivo. This was further confirmed
in vitro. DT treatment in transplanted mice (both Batf3/
 and H-2KBm1) was performed at day 12, to remove
donor DCs, and 2 days later CD11c+ DCs were isolated
from dLNs and co-cultured with T cells isolated from
OT-1Rag/ mice. T cell proliferation and cytokine pro-
duction (IFNc) were measured in vitro after 3 days of co-
culture (Figure 4B). DCs isolated from the dLNs of both
Batf3/ and H-2KBm1 mice treated with DT were cap-
able of activating OVA-specific T cells to proliferate and
produce IFNc as compared to DCs isolated from non-
transplanted mice (Figure 4B). However, the overall
response was less than that seen with transplanted
mice not treated with DT, where DCs presenting antigen
both directly (donor derived) and via acquisition (recipient
DCs) were present. These data confirm that recipient
DCs were capable of acquiring MHC:OVA complexes
from transplanted tissue and, together with direct pre-
sentation of antigen from donor DCs, activates antigen-
specific CD8+ T cells.
Having established that donor MHC-class I transfer is
functional on recipient DCs and drives CD8+ T cell activa-
tion, we then directly measured the transfer of
Figure 4: Acquisition of donor MHC-class I molecules by recipient DCs activates antigen-specific T cells. (A) H-2KBm1 mice
received an Act-mOVAxDTR/GFP skin transplant and 14 posttransplant mice received 4 ng/g of DT (left panels) 24 h prior to injection of
CFSE-labeled OT-1Rag/ T cells. Control, transplanted mice received no DT (middle panels). After 3 days, proliferation of OT-1Rag/ T
cells, identified using antibodies to Va2 and CD8, in the spleen (SPLN) and draining lymph node cells (LNs) was measured by flow
cytometry. Control mice received CFSE-labeled OT-1Rag/ T cells only (right panels). Histograms shown represent the proliferation of
CD8a, Va2, and CFSE-positive cells for an individual mouse. The percentage proliferation of OT-1Rag/ T cells, from three mice per
group, is shown. Each dot represents an individual mouse. Statistical analysis using an unpaired t-test with no significant difference is
denoted as NS. (B) H-2KBm1 (Bm1, black column) and Batf3/ (white column) mice received an Act-mOVAxDTR/GFP skin transplant
and 12 days later some mice received 4 ng/g of DT. Forty-eight hours following DT injection, dLNs were harvested and CD11c+ DCs
were isolated. CD11c+ DCs were used to stimulate OT-1 T cells at a 1:1 ratio in vitro and proliferation was measured on day 3 using 3H
incorporation. Control CD11c+ DCs were isolated from unmanipulated mice. Data shown represent a pool of three individual experiments
and mean (CPM)  1 SEM are shown. IFNc present in culture supernatant was measured using a specific ELISA and is expressed in
pg/mL. Data shown represent a pool of three individual experiments and mean (CPM)  1 SEM are shown. Statistical analysis using an
unpaired t-test with significance denoted as p < 0.001 by ***. No significant difference is denoted as NS. (C) CD11c.DTR.GFP mice
received a B6.Kd skin transplant and 7 days later some mice received a picryl chloride application to the grafted tissue. Four days follow-
ing treatment, RBC-depleted splenocytes were stained with antibodies to CD11c and Kd. Splenocytes from nontransplanted and non-
treated mice were used as controls. The data represent the profile of Kd expression on viable CD11c+GFP+ cells. Statistical analysis
using an unpaired t-test with significance denoted as p = 0.038 by *. No significant difference is denoted as NS. CPM, counts per
minute; DCs, dendritic cells; DT, diphtheria toxin; ELISA, enzyme-linked immunosorbent assay; IFNc, interferon c; RBC, red blood cell.
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MHC-class I molecules and addressed whether inflam-
mation influences this phenomenon. To do so, skin trans-
plants from B6.Kd transgenic mice (B6 mice expressing
H-2Kd) into CD11c.DTR.GFP recipient mice were
performed and the Kd expression on GFP+ve CD11c+
cells was measured by flow cytometry following staining
with anti-Kd antibodies. As expected, we found that
recipient GFP+CD11c+ DCs, present in the spleen,
A
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acquired Kd (Figure 4B, middle panel) following transplan-
tation, with an increase in the number of recipient DCs
expressing Kd being observed (3.74–16.2%) when the
skin irritant picryl chloride was administered to the trans-
planted Kd skin (Figure 4C, last panel). We conclude that
during transplantation recipient DCs can acquire intact
allo-MHC-class I molecules from graft parenchyma and
that under inflammatory conditions this acquisition is
enhanced.
Discussion
In this study we have demonstrated, for the first time,
that following transplantation, donor MHC-class I acquisi-
tion by recipient DCs occurs throughout the life span of
the transplant. We observed, using an OVA antigen skin
transplant model, that acquired MHC-class I:OVA com-
plexes on recipient DCs were the main source of antigen
capable of inducing antigen-specific CD8+ T cells. In
addition, we provide evidence for the first time that
inflammation of the graft contributes to the transfer of
MHC-class I molecules using Kd skin as model antigen.
Taken together, the data presented here argue that the
direct pathway, as a consequence of acquisition of MHC
class I, together with the indirect pathway are major dri-
vers of alloimmunity and should be considered when
designing tolerance-promoting protocols.
In this study, we have shown that removing donor DCs
in both the Batf3/ and H-2KBm1 in vivo skin models
did not substantially reduce antigen-specific in vivo T
cell proliferation, suggesting that donor DCs may not
monopolize initiation of the direct alloresponse. It should
be noted that in our model, DT injection depletes
mostly dermal DCs, with minimal effect on epidermal
Langerhans cells. The lack of an essential role for donor
DCs in transplant rejection has been shown by others
using several murine transplantation models including
heart, skin, and kidney. One example was highlighted
using a model similar to ours. Garrod et al made use of
the CD11c.DTR mice to selectively deplete donor DCs
in heart allografts using DT (16). These authors did not
report a delay in rejection by removing donor DCs, sug-
gesting that donor DCs, in contrast to what has previ-
ously been reported, are not essential for initiating
alloimmune responses.
As discussed in the Introduction, intact allo-MHC-class I
may be acquired by several different routes, including
delivery of these molecules by skin donor dermal DCs to
recipient resident DCs. It has been reported that donor
DCs that migrate out of transplanted organs, in a fully
mismatched setting, are quickly killed by natural killer
cells in the secondary lymphoid tissues of the recipient
(16). In the skin model described here, donor DCs are
present up to 14 days posttransplant, suggesting that
acquisition of MHC class I by resident recipient DCs
from these donor cells may occur and contribute to the
rejection of OVA skin transplants. It is also possible that
recipient B cells also acquire donor MHC class, and this
warrants further investigation.
Depleting recipient DCs has been shown to significantly
prolong graft survival (16). Our transplant data suggest
that this may be due to the removal of recipient DCs that
have acquired donor MHC-class I molecules. Our data
seem to be in contrast to the work presented by Kurts
et al (17). These authors showed that when TCR-
transgenic OT-1 T cells, specific for an OVA peptide pre-
sented by H-2Kb, were injected into mice transgenic for
OVA expressed in the pancreas, the transferred T cells
divided vigorously in the draining lymph node. This was
presumed to result from the capture and processing of
OVA by trafficking DCs. However, if the OVA-transgenic
mice were made chimeric with H-2KBm1 bone marrow
(KBm1 cannot present the OVA peptide to OT-1 T cells),
no OT-1 T cell division was seen. This suggested that
the trafficking of KBm1 expressing DCs did not acquire
intact complexes of Kb with OVA peptides from the pan-
creatic b cells in sufficient quantities to induce OT-1 T
cell proliferation (17). This observation led to the idea that
MHC-class I transfer in vivo may be more efficient under
inflammatory conditions as compared with the steady
state. Indeed, we demonstrate the importance of inflam-
mation by using the skin irritant picryl chloride. This treat-
ment led to a fivefold increase in acquired MHC-class I
molecules in a skin transplant setting, further extending
our previous findings (5). As immunosuppressive drugs
are used extensively following organ transplantation,
testing whether MHC transfer occurs under these condi-
tions will help elucidate the role of the semidirect path-
way in solid organ rejection.
An important question that has not yet been addressed
is how the transfer of MHC-class I:peptide complexes
occurs in vivo. Indeed, whether the transfer occurs
directly via cell-to-cell interaction including membrane
“nibbling” (18,19) or through production of either apop-
totic bodies or exosomes warrants further investigation
(20,21). Whether specific receptors are involved in the
uptake of MHC:peptide complexes and whether inflam-
mation influences any of the aforementioned mecha-
nisms are questions that need further investigation.
Although bone marrow–DCs have been shown to pro-
duce exosomes containing MHC-class I molecules
(22,23), Wakim and Bevan observed using an in vitro
transwell system that direct contact, rather than exo-
somes release and acquisition, was important for the
transfer of MHC-class I molecules (24). However, given
that this experimental system may limit exosome trans-
fer, the question of whether exosomes or apoptotic bod-
ies released from donor DCs or parenchymal cells in situ
contribute to the semidirect pathway is something that
warrants further investigation. This has recently been
addressed with respect to donor DCs (25).
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In summary, we have demonstrated for the first time
that MHC transfer lasts at least for the life of the trans-
plant, activating CD8+ T cells with specificity against
MHC-class I:peptide complexes transferred from the
graft to recipient antigen presenting cells for the duration
of the graft. Furthermore, we have proven that inflamma-
tion of the graft further increased the amount of MHC
transfer. Altogether, the data presented here extend our
previous observations, further emphasizing that both the
indirect and the direct pathway of allorecognition are
likely to persist for the life of a transplant. Consequently,
both pathways need to be regulated if transplantation tol-
erance is to be achieved.
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